| Prehospital treatment with zalunfiban (RUC-4) in patients with ST‐elevation myocardial infarction undergoing primary percutaneous coronary intervention: Rationale and design of … SAOF Rikken, A Selvarajah, RS Hermanides, BS Coller, CM Gibson, ... American Heart Journal 258, 119-128, 2023 | 6 | 2023 |
| Dual versus triple antithrombotic therapy after percutaneous coronary intervention: the prospective multicentre WOEST 2 Study WL Bor, AJW de Veer, RH Olie, SAOF Rikken, DRPPCP Yin, ... EuroIntervention 18 (4), e303, 2022 | 5 | 2022 |
| Parenteral antiplatelet drugs in ST-elevation myocardial infarction: current status and future directions SAOF Rikken, RF Storey, F Andreotti, P Clemmensen, JM Ten Berg Thrombosis and Haemostasis 123 (02), 150-158, 2023 | 4 | 2023 |
| Prepercutaneous coronary intervention Zalunfiban dose-response relationship to target vessel blood flow at initial angiogram in st-elevation myocardial infarction–A post hoc … SAOF Rikken, WL Bor, A Selvarajah, KL Zheng, AP Hack, CM Gibson, ... American Heart Journal 262, 75-82, 2023 | 2 | 2023 |
| Comparison of the effects of the GPIIb-IIIa antagonist Zalunfiban and the P2Y12 antagonist Selatogrel on Platelet Aggregation BJ Curry, AOFS Rikken, CM Gibson, CB Granger, AWJ van ‘t Hof, ... Journal of Thrombosis and Thrombolysis 56 (4), 499-510, 2023 | 1 | 2023 |
| Optimizing Antiplatelet Pretreatment in STEMI: The Crucial Role of Timing and Agent Selection SAOF Rikken, JM ten Berg, AWJ van 't Hof J Am Coll Cardiol Intv 17 (6), 820–821, 2024 | | 2024 |
| Critical Analysis of Thrombocytopenia Associated With Glycoprotein IIb/IIIa Inhibitors and Potential Role of Zalunfiban, a Novel Small Molecule Glycoprotein Inhibitor, in … SAOF Rikken, AWJ van't Hof, JM Ten Berg, DJ Kereiakes, BS Coller Journal of the American Heart Association 12 (24), e031855, 2023 | | 2023 |
